Measuring NAFLD models of care

Alina M. Allen; Zobair M. Younossi; Emmanuel A. Tsochatzis; William Alazawi; Shira Zelber-Sagi; Juan Pablo Arab; Kenneth Cusi; Jeffrey V. Lazarus

doi:https://doi.org/10.1038/s41575-023-00798-9

Measuring NAFLD models of care

Alina M. Allen, Zobair M. Younossi, Emmanuel A. Tsochatzis, William Alazawi, Shira Zelber-Sagi, Juan Pablo Arab, Kenneth Cusi, Jeffrey V. Lazarus

School of Public Health

University of Haifa

Research output: Contribution to journal › Comment/debate

Original language	American English
Pages (from-to)	626-627
Number of pages	2
Journal	Nature Reviews Gastroenterology and Hepatology
Volume	20
Issue number	10
Early online date	8 Jun 2023
DOIs	https://doi.org/10.1038/s41575-023-00798-9
State	Published - Oct 2023

All Science Journal Classification (ASJC) codes

Gastroenterology
Hepatology

Access to Document

https://doi.org/10.1038/s41575-023-00798-9

Cite this

@article{42c23745547847f7869e23b1824f971f,

title = "Measuring NAFLD models of care",

author = "Allen, {Alina M.} and Younossi, {Zobair M.} and Tsochatzis, {Emmanuel A.} and William Alazawi and Shira Zelber-Sagi and Arab, {Juan Pablo} and Kenneth Cusi and Lazarus, {Jeffrey V.}",

note = "Funding Information: A.M.A. has received grant support to her institution from the National Institutes of Health (NIH) (DK128127), Novo Nordisk, Pfizer and Target Pharma and has participated in advisory boards for Novo Nordisk, outside of the submitted work. Z.M.Y. has received consulting fees from Gilead, Intercept, Siemens, Novo Nordisk, Madrigal, Merck, Quest and Bristol Myers Squibb, outside of the submitted work. E.A.T. has participated in advisory boards for and received consulting fees from Boehringer, Pfizer and Novo Nordisk and has given lectures for Novo Nordisk and Dr Falk, outside of the submitted work. S.Z-S. has given presentations for and received meeting and/or travel support from AbbVie, outside of the submitted work. K.C. has received grant support to his institution from Echosens, Inventiva, Poxel, Novo, Labcorp and Zydus, consulting fees from BMS, Lilly, Madrigal, Merck, Myovant, Novo Nordisk, Prosciento, Quest, Sagimet, Sonic Incytes and Terns and other support from Echosens, Inventiva, Poxel, Labcorp and Zydus, outside of the submitted work. J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics to his institution, speaker fees from Intercept, Janssen, Novo Nordisk and ViiV and consulting fees from Novavax, outside of the submitted work. J.V.L. also acknowledges support to ISGlobal from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033 and the “Generalitat de Catalunya” through the CERCA programme, outside of the submitted work. W.A. and J.P.A. declare no competing interests.",

year = "2023",

month = oct,

doi = "https://doi.org/10.1038/s41575-023-00798-9",

language = "American English",

volume = "20",

pages = "626--627",

journal = "Nature Reviews Gastroenterology and Hepatology",

issn = "1759-5045",

publisher = "Nature Research",

number = "10",

}

TY - JOUR

T1 - Measuring NAFLD models of care

AU - Allen, Alina M.

AU - Younossi, Zobair M.

AU - Tsochatzis, Emmanuel A.

AU - Alazawi, William

AU - Zelber-Sagi, Shira

AU - Arab, Juan Pablo

AU - Cusi, Kenneth

AU - Lazarus, Jeffrey V.

N1 - Funding Information: A.M.A. has received grant support to her institution from the National Institutes of Health (NIH) (DK128127), Novo Nordisk, Pfizer and Target Pharma and has participated in advisory boards for Novo Nordisk, outside of the submitted work. Z.M.Y. has received consulting fees from Gilead, Intercept, Siemens, Novo Nordisk, Madrigal, Merck, Quest and Bristol Myers Squibb, outside of the submitted work. E.A.T. has participated in advisory boards for and received consulting fees from Boehringer, Pfizer and Novo Nordisk and has given lectures for Novo Nordisk and Dr Falk, outside of the submitted work. S.Z-S. has given presentations for and received meeting and/or travel support from AbbVie, outside of the submitted work. K.C. has received grant support to his institution from Echosens, Inventiva, Poxel, Novo, Labcorp and Zydus, consulting fees from BMS, Lilly, Madrigal, Merck, Myovant, Novo Nordisk, Prosciento, Quest, Sagimet, Sonic Incytes and Terns and other support from Echosens, Inventiva, Poxel, Labcorp and Zydus, outside of the submitted work. J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics to his institution, speaker fees from Intercept, Janssen, Novo Nordisk and ViiV and consulting fees from Novavax, outside of the submitted work. J.V.L. also acknowledges support to ISGlobal from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033 and the “Generalitat de Catalunya” through the CERCA programme, outside of the submitted work. W.A. and J.P.A. declare no competing interests.

PY - 2023/10

Y1 - 2023/10

UR - http://www.scopus.com/inward/record.url?scp=85161422674&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41575-023-00798-9

DO - https://doi.org/10.1038/s41575-023-00798-9

M3 - Comment/debate

C2 - 37291278

SN - 1759-5045

VL - 20

SP - 626

EP - 627

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

IS - 10

ER -

Measuring NAFLD models of care

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this